{"doi":"10.21037/tlcr-24-34","title":"A novel HLA-DQB2::MET gene fusion variant in lung adenocarcinoma with prolonged response to tepotinib: a case report","abstract":"Background: MET rearrangements are infrequently observed in non-small cell lung cancer (NSCLC). Advanced genomic detection techniques have unveiled such infrequent genomic variations, particularly MET fusions in approximately 0.5% of NSCLC patients. Tyrosine kinase inhibitors (TKIs) have revolutionized the standard of care in lung cancer and more recently a second generation MET TKI tepotinib received Food and Drug Administration (FDA) approval for MET exon 14 alterations in metastatic NSCLC. Despite this, the therapeutic landscape for MET-rearranged NSCLC patients remains significantly unexplored. The aim of our report is to detail a unique case of a patient with metastatic lung adenocarcinoma with a novel HLA-DQB2::MET fusion detected by next-generation sequencing (NGS) following previous treatment resistance. Case Description: A 73-year-old female was initially started on carboplatin, pemetrexed and pembrolizumab with maintenance, but eventually had progression in the left upper lobe (LUL). Upon progression she was enrolled in a clinical trial of a monoclonal antibody with or without a PD-1 inhibitor, but brain metastasis progression was eventually detected by magnetic resonance imaging (MRI) requiring stereotactic radiosurgery (SRS) and a craniotomy. The trial drug was eventually discontinued due to progression and toxicity and NGS on bronchoscopy tissue revealed HLA-DQB2::MET fusion. The patient was initiated on tepotinib and continues with clinical and radiological stable disease for over 12 months. The patient’s response to a MET inhibitor, tepotinib, underscores the potential efficacy of selective MET inhibitors for individuals with previously unexplored MET fusions. Conclusions: The positive response to tepotinib of a patient with NSCLC harboring a novel MET-Fusion underscores the importance of the use of comprehensive next-generational sequencing-based panels and highlights the necessity for additional research and clinical exploration of selective MET inhibitors for managing NSCLC with MET rearrangements.","journal":"Translational Lung Cancer Research","year":2024,"id":461002,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9548,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":317443,"name":"Isa Mambetsariev","orcid":"0000-0003-2882-0249","position":1,"is_corresponding":false},{"id":317444,"name":"Jeremy Fricke","orcid":"0000-0003-4684-8114","position":2,"is_corresponding":false},{"id":1077437,"name":"Razmig Babikian","orcid":null,"position":3,"is_corresponding":false},{"id":950716,"name":"Shaira Therese Dingal","orcid":null,"position":4,"is_corresponding":false},{"id":1289947,"name":"Farhad Mazdisnian","orcid":null,"position":5,"is_corresponding":false},{"id":249978,"name":"Behnam Badie","orcid":"0000-0001-9811-9306","position":6,"is_corresponding":false},{"id":463012,"name":"Leonidas Arvanitis","orcid":"0000-0002-4744-8350","position":7,"is_corresponding":false},{"id":780091,"name":"Michelle Afkhami","orcid":"0000-0001-5830-6158","position":8,"is_corresponding":false},{"id":420029,"name":"Miguel A. Villalona‐Calero","orcid":"0000-0002-1991-5070","position":9,"is_corresponding":false},{"id":108575,"name":"Ravi Salgia","orcid":"0000-0001-9643-7626","position":10,"is_corresponding":false},{"id":1289556,"name":"Douglas Dias e Silva","orcid":"0000-0001-9536-6504","position":0,"is_corresponding":true}],"reference_count":20,"raw_metadata":null,"created_at":"2026-07-19T02:04:12.271488Z","pmid":"38854944","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}